Unknown

Dataset Information

Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma.


ABSTRACT:

Background

TP53 is frequently altered in esophageal squamous cell carcinoma (ESCC). However, the landscape of TP53 mutation and its effects on patients remain controversial.

Methods

Somatic mutations of TP53 in 161 patients with resectable ESCC were identified by next-generation sequencing (NGS) and verified by immunohistochemistry (IHC). Patients were stratified into seven TP53 mutations, and depending on the extent of the effect on the encoded protein, it was divided into "disruptive" and "non-disruptive" types. The association of TP53 mutation with clinicopathological properties and disease outcome was investigated.

Results

TP53 mutations were discovered in 85.7% patients, of which 68.9% carried mutations in the DNA-binding

SUBMITTER: Huang M 

PROVIDER: S-EPMC7186752 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature